DK1695979T3 - Gappede modificerede oligonukleotider - Google Patents

Gappede modificerede oligonukleotider

Info

Publication number: DK1695979T3
Authority: DK; Denmark
Prior art keywords: oligonucleotides; gapped; macromolecules; modified oligonucleotides; erythro
Prior art date: 1991-12-24

Application number

DK06075176.5T

Other languages

English (en)

Inventor

Brett P Monia

Phillip Dan Cook

Original Assignee

Isis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-12-24

Filing date

1992-12-23

Publication date

2011-10-10

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25216474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1695979(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1992-12-23 Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc

2011-10-10 Application granted granted Critical

2011-10-10 Publication of DK1695979T3 publication Critical patent/DK1695979T3/da

Links

JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 3
108091034117 Oligonucleotide Proteins 0.000 abstract 2
229920002521 macromolecule Polymers 0.000 abstract 2
102100034343 Integrase Human genes 0.000 abstract 1
101710163270 Nuclease Proteins 0.000 abstract 1
230000000692 anti-sense effect Effects 0.000 abstract 1
230000000295 complement effect Effects 0.000 abstract 1
238000001514 detection method Methods 0.000 abstract 1
238000003745 diagnosis Methods 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
239000002773 nucleotide Substances 0.000 abstract 1
125000003729 nucleotide group Chemical group 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
125000001424 substituent group Chemical group 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6832—Enhancement of hybridisation reaction
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3527—Other alkyl chain
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3531—Hydrogen
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/125—Modifications characterised by incorporating agents resulting in resistance to degradation

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Analytical Chemistry (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
General Chemical & Material Sciences (AREA)
Gastroenterology & Hepatology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Plant Pathology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)

DK06075176.5T 1991-12-24 1992-12-23 Gappede modificerede oligonukleotider DK1695979T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US81496191A	1991-12-24	1991-12-24
EP00202252A EP1044987B1 (en)	1991-12-24	1992-12-23	Gapped 2'-modified oligonucleotides

Publications (1)

Publication Number	Publication Date
DK1695979T3 true DK1695979T3 (da)	2011-10-10

Family

ID=25216474

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK06075176.5T DK1695979T3 (da)	1991-12-24	1992-12-23	Gappede modificerede oligonukleotider
DK93902851.0T DK0618925T4 (da)	1991-12-24	1992-12-23	Antisense-oligonukleotider

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DK93902851.0T DK0618925T4 (da)	1991-12-24	1992-12-23	Antisense-oligonukleotider

Country Status (10)

Country	Link
US (4)	US6146829A (da)
EP (3)	EP1044987B1 (da)
JP (2)	JP3131222B2 (da)
KR (1)	KR940703846A (da)
AT (3)	ATE515510T1 (da)
AU (1)	AU669353B2 (da)
CA (1)	CA2126691C (da)
DE (2)	DE69232032T3 (da)
DK (2)	DK1695979T3 (da)
WO (1)	WO1993013121A1 (da)

Families Citing this family (526)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5959096A (en) *	1992-03-16	1999-09-28	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides against human protein kinase C
US7015315B1 (en)	1991-12-24	2006-03-21	Isis Pharmaceuticals, Inc.	Gapped oligonucleotides
US5700922A (en) *	1991-12-24	1997-12-23	Isis Pharmaceuticals, Inc.	PNA-DNA-PNA chimeric macromolecules
US6277603B1 (en)	1991-12-24	2001-08-21	Isis Pharmaceuticals, Inc.	PNA-DNA-PNA chimeric macromolecules
US20070032446A1 (en) *	1991-12-24	2007-02-08	Isis Pharmaceuticals, Inc.	Gapped 2' modified oligonucleotides
CA2126691C (en) *	1991-12-24	2003-05-06	Phillip Dan Cook	Gapped 2' modified oligonucleotides
US5681747A (en) *	1992-03-16	1997-10-28	Isis Pharmaceuticals, Inc.	Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
US6153599A (en) *	1992-03-16	2000-11-28	Isis Pharmaceuticals, Inc.	Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US5885970A (en) *	1992-03-16	1999-03-23	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides against human protein kinase C
US6117847A (en) *	1992-03-16	2000-09-12	Isis Pharmaceuticals, Inc.	Oligonucleotides for enhanced modulation of protein kinase C expression
US5882927A (en) *	1992-03-16	1999-03-16	Isis Pharmaceuticals, Inc.	Oligonucleotide inhibition of protein kinase C
US5916807A (en) *	1992-03-16	1999-06-29	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides against human protein kinase C
US5922686A (en) *	1992-03-16	1999-07-13	Isis Pharmaceuticals, Inc.	Oligonucleotide modulation of protein kinase C
US5948898A (en) *	1992-03-16	1999-09-07	Isis Pharmaceuticals, Inc.	Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
TW244371B (da) *	1992-07-23	1995-04-01	Tri Clover Inc
HUT73335A (en) *	1992-10-05	1996-07-29	Isis Pharmaceuticals Inc	Antisense oligonucleotides and methods for inhibition of the human ras genes, methods for inhibition of tumour-cells proliferation and methods for detection of activated ras-genes
DE59407895D1 (de) *	1993-05-12	1999-04-15	Novartis Ag	Nukleoside und Oligonukleotide mit 2'-Ethergruppen
US6294664B1 (en)	1993-07-29	2001-09-25	Isis Pharmaceuticals, Inc.	Synthesis of oligonucleotides
EP0743859A4 (en) *	1993-11-16	1998-10-21	Genta Inc	CHEMICAL OLIGONUCLEOSIDE COMPOUNDS
US6410518B1 (en) *	1994-05-31	2002-06-25	Isis Pharmaceuticals, Inc.	Antisense oligonucleotide inhibition of raf gene expression
US5652356A (en) *	1995-08-17	1997-07-29	Hybridon, Inc.	Inverted chimeric and hybrid oligonucleotides
US7074768B2 (en)	1995-08-17	2006-07-11	Idera Pharmaceuticals, Inc.	Modified protein kinase A-specific oligonucleotides and methods of their use
US6624293B1 (en)	1995-08-17	2003-09-23	Hybridon, Inc.	Modified protein kinase A-specific oligonucleotides and methods of their use
US5856099A (en) *	1996-05-21	1999-01-05	Isis Pharmaceuticals, Inc.	Antisense compositions and methods for modulating type I interleukin-1 receptor expression
EP0906329B1 (en)	1996-06-06	2003-10-08	Novartis AG	2'-substituted nucleosides and oligonucleotide derivatives
WO1998002582A2 (en)	1996-07-16	1998-01-22	Gen-Probe Incorporated	Methods for detecting and amplifying nucleic acid sequences using modified oligonucleotides having increased target specific t¿m?
US7070925B1 (en)	1996-07-16	2006-07-04	Gen-Probe Incorporated	Method for determining the presence of an RNA analyte in a sample using a modified oligonucleotide probe
US6025133A (en) *	1996-12-30	2000-02-15	Gen-Probe Incorporated	Promoter-sequestered oligonucleoside and method of use
ES2402947T3 (es)	1997-04-10	2013-05-10	Stichting Katholieke Universiteit University Medical Centre Nijmegen	PCA3, genes PCA3 y métodos de uso
DE19741739B4 (de) *	1997-09-22	2006-04-27	Nanogen Recognomics Gmbh	Supramolekulares Paarungssystem, dessen Herstellung und Verwendung
US6007992A (en) *	1997-11-10	1999-12-28	Gilead Sciences, Inc.	Pyrimidine derivatives for labeled binding partners
US6028183A (en) *	1997-11-07	2000-02-22	Gilead Sciences, Inc.	Pyrimidine derivatives and oligonucleotides containing same
US6007995A (en) *	1998-06-26	1999-12-28	Isis Pharmaceuticals Inc.	Antisense inhibition of TNFR1 expression
US6043352A (en) *	1998-08-07	2000-03-28	Isis Pharmaceuticals, Inc.	2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
US6673912B1 (en)	1998-08-07	2004-01-06	Isis Pharmaceuticals, Inc.	2′-O-aminoethyloxyethyl-modified oligonucleotides
US6623920B1 (en) *	1999-07-09	2003-09-23	Gen-Probe Incorporated	Detection of HIV-1 by nucleic acid amplification
DE60027027T2 (de)	1999-09-29	2006-11-30	Diagnocure Inc.	Pca3 mrna in gutartigen und bösartigen prostatageweben
AU7104200A (en)	2000-09-01	2002-03-22	Gen Probe Inc	Amplification of hiv-1 sequences for detection of sequences associated with drug-resistance mutations
US6582920B2 (en)	2000-09-01	2003-06-24	Gen-Probe Incorporated	Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
WO2002020543A2 (en) *	2000-09-07	2002-03-14	Avecia Biotechnology Inc.	Synthons for oligonucleotide synthesis
US20050288242A1 (en) *	2001-05-18	2005-12-29	Sirna Therapeutics, Inc.	RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
DE10159904A1 (de) *	2001-12-06	2003-07-03	Adnagen Ag	Oligonukleotidanordnung, Verfahren zum Nukleotidnachweis sowie Vorrichtung hierfür
US20090093439A1 (en) *	2002-02-20	2009-04-09	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF CHROMOSOME TRANSLOCATION GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20090137513A1 (en) *	2002-02-20	2009-05-28	Sirna Therapeutics, Inc.	RNA Interference Mediated Inhibition of Acetyl-CoA-Carboxylase Gene Expression Using Short Interfering Nucleic Acid (siNA)
US20090137507A1 (en) *	2002-02-20	2009-05-28	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF ANGIOPOIETIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP1432724A4 (en) *	2002-02-20	2006-02-01	Sirna Therapeutics Inc	INTERFERENCE MEDIATION INHIBITION OF GENE RNA FROM MAP KINASE
US20090306182A1 (en) *	2002-02-20	2009-12-10	Sirna Therapeutics, Inc.	RNA INTERFERENCE MEDIATED INHIBITION OF MAP KINASE GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7199107B2 (en)	2002-05-23	2007-04-03	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
US7163927B2 (en) *	2002-05-23	2007-01-16	Isis Pharmaceuticals, Inc.	Antisense modulation of kinesin-like 1 expression
US20040029111A1 (en)	2002-06-14	2004-02-12	Linnen Jeffrey M.	Compositions and methods for detecting hepatitis B virus
CN100543137C (zh)	2002-08-05	2009-09-23	阿图根股份公司	其它新形式的干扰rna分子
EP3241915B1 (en)	2002-10-16	2021-06-23	Gen-Probe Incorporated	Compositions and methods for detecting west nile virus
DK1569661T3 (da)	2002-11-18	2010-01-11	Santaris Pharma As	Antisense design
WO2004070056A2 (en)	2003-02-07	2004-08-19	Diagnocure Inc.	Method to detect prostate cancer in a sample
EP1648914A4 (en)	2003-07-31	2009-12-16	Regulus Therapeutics Inc	OLIGOMERIC COMPOUNDS AND COMPOSITIONS USEFUL FOR MODULATING SMALL NON-CODING RNA
DE602004028862D1 (de)	2003-12-19	2010-10-07	Gen Probe Inc	Der nukleinsäuren von hiv-1 und hiv-2
NZ597400A (en)	2004-02-18	2013-06-28	Chromocell Corp	Methods and Materials Using Signaling Probes
US8790919B2 (en) *	2004-03-15	2014-07-29	Isis Pharmaceuticals, Inc.	Compositions and methods for optimizing cleavage of RNA by RNase H
KR101147147B1 (ko) *	2004-04-01	2012-05-25	머크 샤프 앤드 돔 코포레이션	Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
US7741299B2 (en)	2004-08-16	2010-06-22	Quark Pharmaceuticals, Inc.	Therapeutic uses of inhibitors of RTP801
CA2582055C (en)	2004-09-30	2014-04-08	Gen-Probe Incorporated	Assay for detecting and quantifying hiv-1
CA2582661C (en)	2004-11-09	2015-08-11	Gen-Probe Incorporated	Compositions and methods for detecting group a streptococci
US7923207B2 (en)	2004-11-22	2011-04-12	Dharmacon, Inc.	Apparatus and system having dry gene silencing pools
US7923206B2 (en)	2004-11-22	2011-04-12	Dharmacon, Inc.	Method of determining a cellular response to a biological agent
US7935811B2 (en)	2004-11-22	2011-05-03	Dharmacon, Inc.	Apparatus and system having dry gene silencing compositions
CA2491067A1 (en)	2004-12-24	2006-06-24	Stichting Katholieke Universiteit	Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
DE602006018586D1 (de)	2005-02-07	2011-01-13	Gen Probe Inc	Zusammensetzungen und verfahren zum nachweis von streptokokken der gruppe b
US8124335B2 (en)	2005-05-06	2012-02-28	Gen-Probe Incorporated	Compositions and assays to detect influenza virus A and B nucleic acids
CA2625414A1 (en)	2005-10-17	2007-04-26	Gen-Probe Incorporated	Compositions and methods to detect legionella pneumophila nucleic acid
WO2007047913A2 (en) *	2005-10-20	2007-04-26	Isis Pharmaceuticals, Inc	Compositions and methods for modulation of lmna expression
NL2000439C2 (nl)	2006-01-20	2009-03-16	Quark Biotech	Therapeutische toepassingen van inhibitoren van RTP801.
WO2008029276A2 (en)	2006-02-02	2008-03-13	Allergan, Inc.	Compositions and methods for the treatment of ophthalmic disease
US7588897B2 (en)	2006-05-12	2009-09-15	Gen-Probe Incorporated	Compositions and methods to detect Enterococci nucleic acid
JP2009544281A (ja)	2006-07-21	2009-12-17	サイレンス・セラピューティクス・アーゲー	プロテインキナーゼ３の発現を阻害するための手段
CA2658105C (en)	2006-08-01	2016-07-05	Gen-Probe Incorporated	Methods of nonspecific target capture of nucleic acids
JP5352462B2 (ja)	2006-09-22	2013-11-27	ダーマコン，インコーポレイテッド	二本鎖オリゴヌクレオチド複合体、ｒｎａ干渉による遺伝子サイレンシング方法、および医薬品組成物
JP2010507387A (ja)	2006-10-25	2010-03-11	クアーク・ファーマスーティカルス、インコーポレイテッド	新規のｓｉＲＮＡおよびその使用方法
EP2407558A1 (en)	2006-10-31	2012-01-18	Noxxon Pharma AG	Methods for the detection of a single- or double-stranded nucleic acid molecule
US9938641B2 (en)	2006-12-18	2018-04-10	Fluidigm Corporation	Selection of aptamers based on geometry
EP2121956B1 (en)	2006-12-21	2016-08-17	Gen-Probe Incorporated	Methods and compositions for nucleic acid amplification
US11078262B2 (en)	2007-04-30	2021-08-03	Allergan, Inc.	High viscosity macromolecular compositions for treating ocular conditions
JP2010538678A (ja) *	2007-09-18	2010-12-16	イントラドイグムコーポレーション	Ｋ−ｒａｓｓｉＲＮＡ含有組成物及びそれらの使用法
US20100280097A1 (en) *	2007-09-18	2010-11-04	Intradigm Corporation	Compositions comprising hif-1 alpha sirna and methods of use thereof
BRPI0817605A2 (pt)	2007-10-03	2017-05-09	Quark Pharmaceuticals Inc	novas estruturas de sirna
JP2011503000A (ja) *	2007-11-02	2011-01-27	セントコア・オーソ・バイオテツク・インコーポレーテツド	半合成ＧＬＰ−１ペプチド−Ｆｃ融合コンストラクト、その方法及び使用
AU2008343380B2 (en)	2007-12-26	2012-07-12	Gen-Probe Incorporated	Compositions and methods to detect Candida albicans nucleic acid
US8188060B2 (en)	2008-02-11	2012-05-29	Dharmacon, Inc.	Duplex oligonucleotides with enhanced functionality in gene regulation
WO2009114726A1 (en) *	2008-03-12	2009-09-17	Intradigm Corporation	Compositions comprising notch1 sirna and methods of use thereof
US9273365B2 (en)	2008-04-21	2016-03-01	Gen-Probe Incorporated	Method for detecting Chikungunya virus
US8097412B2 (en)	2008-07-12	2012-01-17	Biodiagnostics, Inc.	DNA-based test for detection of annual and intermediate ryegrass
MX2011000603A (es) *	2008-07-18	2011-03-02	Oncogenex Technologies Inc	Formulacion antisentido.
ES2616051T3 (es)	2008-12-02	2017-06-09	Wave Life Sciences Japan, Inc.	Método para la síntesis de ácidos nucleicos modificados en el átomo de fósforo
US20110288155A1 (en)	2008-12-18	2011-11-24	Elena Feinstein	Sirna compounds and methods of use thereof
WO2010091878A2 (en)	2009-02-13	2010-08-19	Silence Therapeutics Ag	Means for inhibiting the expression of opa1
JP2012517815A (ja)	2009-02-18	2012-08-09	サイレンス・セラピューティクス・アーゲー	Ａｎｇ２の発現を阻害するための手段
EP3257859B1 (en)	2009-02-26	2020-09-23	Gen-Probe Incorporated	Assay for detection of human parvovirus nucleic acid
CA2766391C (en)	2009-07-01	2021-04-20	Gen-Probe Incorporated	Methods and compositions for multiplex nucleic acid amplification
KR101885383B1 (ko)	2009-07-06	2018-08-03	웨이브 라이프 사이언시스 리미티드	신규한 핵산 프로드러그 및 그의 사용 방법
US8236570B2 (en)	2009-11-03	2012-08-07	Infoscitex	Methods for identifying nucleic acid ligands
US8841429B2 (en)	2009-11-03	2014-09-23	Vivonics, Inc.	Nucleic acid ligands against infectious prions
US9910040B2 (en)	2012-07-09	2018-03-06	Sevident, Inc.	Molecular nets comprising capture agents and linking agents
US9733242B2 (en)	2012-10-07	2017-08-15	Sevident, Inc.	Devices for capturing analyte
WO2011066475A1 (en)	2009-11-26	2011-06-03	Quark Pharmaceuticals, Inc.	Sirna compounds comprising terminal substitutions
EP2862929B1 (en)	2009-12-09	2017-09-06	Quark Pharmaceuticals, Inc.	Compositions and methods for treating diseases, disorders or injury of the CNS
EP3012324A3 (en)	2009-12-09	2016-07-06	Nitto Denko Corporation	Modulation of hsp47 expression
WO2011084193A1 (en)	2010-01-07	2011-07-14	Quark Pharmaceuticals, Inc.	Oligonucleotide compounds comprising non-nucleotide overhangs
EP3040425B1 (en)	2010-02-17	2019-08-28	Gen-Probe Incorporated	Compostions and methods to detect atopobium vaginae nucleic acid
US9506057B2 (en)	2010-03-26	2016-11-29	Integrated Dna Technologies, Inc.	Modifications for antisense compounds
US8507663B2 (en)	2010-04-06	2013-08-13	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of CD274/PD-L1 gene
CA3011697C (en)	2010-04-21	2020-04-07	Gen-Probe Incorporated	Compositions, methods and kits to detect herpes simplex virus nucleic acids
JP6081910B2 (ja)	2010-06-02	2017-02-15	アルナイラムファーマシューティカルズ，インコーポレイテッドＡｌｎｙｌａｍＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	肝線維症治療用組成物および肝線維症の治療法
CA2801928C (en)	2010-06-24	2018-04-10	Quark Pharmaceuticals, Inc.	Double stranded rna compounds to rhoa and use thereof
CN102985566B (zh)	2010-06-30	2015-06-17	简.探针公司	使用分析物和过程控制信号的单次读取确定而鉴定含分析物的样品的方法和设备
EP3674423A1 (en)	2010-07-12	2020-07-01	Gen-Probe Incorporated	Compositions and assays to detect seasonal h3 influenza a virus nucleic acid
WO2012017208A1 (en)	2010-08-04	2012-02-09	Cizzle Biotechnology Limited	Methods and compounds for the diagnosis and treatment of
WO2012030856A2 (en)	2010-08-30	2012-03-08	Gen-Probe Incorporated	Compositions, methods and reaction mixtures for the detection of xenotropic murine leukemia virus-related virus
AU2011299233B2 (en)	2010-09-07	2016-09-15	Integrated Dna Technologies, Inc.	Modifications for antisense compounds
CA2811333C (en)	2010-09-16	2020-05-12	Gen-Probe Incorporated	Capture probes immobilizable via l-nucleotide tail
US10428019B2 (en)	2010-09-24	2019-10-01	Wave Life Sciences Ltd.	Chiral auxiliaries
WO2012046219A2 (en)	2010-10-04	2012-04-12	Gen-Probe Prodesse, Inc.	Compositions, methods and kits to detect adenovirus nucleic acids
US20140134231A1 (en)	2010-10-11	2014-05-15	Sanford-Burnham Medical Research Institute	Mir-211 expression and related pathways in human melanoma
EP3388532B1 (en)	2010-11-01	2021-03-10	Gen-Probe Incorporated	Integrated capture and amplification of target nucleic acid for sequencing
US8569220B2 (en)	2010-11-12	2013-10-29	Jelmar, Llc	Hard surface cleaning composition
ES2633565T3 (es)	2010-11-12	2017-09-22	The General Hospital Corporation	ARN no codificantes asociados a polycomb
US9920317B2 (en)	2010-11-12	2018-03-20	The General Hospital Corporation	Polycomb-associated non-coding RNAs
CA2818024C (en)	2010-12-06	2019-09-24	Quark Pharmaceuticals, Inc.	Double stranded oligonucleotide compounds comprising positional modifications
US9193973B2 (en)	2010-12-10	2015-11-24	Alynylam Pharmaceuticals, Inc.	Compositions and methods for increasing erythropoietin (EPO) production
EP2648763A4 (en)	2010-12-10	2014-05-14	Alnylam Pharmaceuticals Inc	COMPOSITIONS AND METHODS FOR EXPRESSION INHIBITION OF GENES KLF-1 AND BCL11A
US9205100B2 (en)	2011-03-03	2015-12-08	Quark Pharmaceuticals, Inc.	Compositions and methods for treating lung disease and injury
AU2012223366B2 (en)	2011-03-03	2017-02-23	Quark Pharmaceuticals, Inc.	Oligonucleotide modulators of the toll-like receptor pathway
EP2683833B1 (en)	2011-03-10	2018-09-26	Gen-Probe Incorporated	Methods for the selection and optimization of oligonucleotide tag sequences
MX343008B (es)	2011-03-29	2016-10-21	Alnylam Pharmaceuticals Inc	Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
AU2012236099A1 (en)	2011-03-31	2013-10-03	Moderna Therapeutics, Inc.	Delivery and formulation of engineered nucleic acids
US10086043B2 (en)	2011-04-03	2018-10-02	The General Hospital Corporation	Efficient protein expression in vivo using modified RNA (MOD-RNA)
EP3604559A1 (en)	2011-04-25	2020-02-05	Gen-Probe Incorporated	Compositions and methods for detecting bv-associated bacterial nucleic acid
TWI658830B (zh)	2011-06-08	2019-05-11	日東電工股份有限公司	Ｈｓｐ47表現調控強化用類視色素脂質體
US10196637B2 (en)	2011-06-08	2019-02-05	Nitto Denko Corporation	Retinoid-lipid drug carrier
SG10201800715PA (en)	2011-06-21	2018-02-27	Alnylam Pharmaceuticals Inc	Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof
EP3597750B1 (en)	2011-06-23	2022-05-04	Alnylam Pharmaceuticals, Inc.	Serpina1 sirnas: compositions of matter and methods of treatment
AU2012284307A1 (en)	2011-07-15	2013-05-09	Gen-Probe Incorporated	Compositions and method for detecting human parvovirus nucleic acid and for detecting hepatitis A virus nucleic acids in single-plex or multiplex assays
CN107365339A (zh)	2011-07-19	2017-11-21	波涛生命科学有限公司	合成官能化核酸的方法
JP2014526887A (ja)	2011-08-01	2014-10-09	アルナイラムファーマシューティカルズ，インコーポレイテッド	造血幹細胞移植の成功率を改善する方法
EP3620533B1 (en)	2011-09-06	2023-01-18	Gen-Probe Incorporated	Closed nucleic acid structures
EP2753714B1 (en)	2011-09-06	2017-04-12	Gen-Probe Incorporated	Circularized templates for sequencing
EP3255155B1 (en)	2011-09-08	2019-04-24	Gen-Probe Incorporated	Compositions and methods for detecting bv-associated bacterial nucleic acid
CA2848753C (en)	2011-09-14	2022-07-26	Rana Therapeutics, Inc.	Multimeric oligonucleotide compounds
WO2013059740A1 (en)	2011-10-21	2013-04-25	Foundation Medicine, Inc.	Novel alk and ntrk1 fusion molecules and uses thereof
BR112014010769B1 (pt)	2011-11-03	2021-08-03	Quark Pharmaceuticals, Inc	Uso de um composto de rna de fita dupla para preparar um medicamento para tratar doença de ménière
EP3848474A1 (en)	2011-11-04	2021-07-14	Gen-Probe Incorporated	Molecular assay reagents and methods
WO2013070821A1 (en)	2011-11-08	2013-05-16	Quark Pharmaceuticals, Inc.	Methods and compositions for treating diseases, disorders or injury of the nervous system
DE102011120550B4 (de)	2011-12-05	2013-11-07	Gen-Probe Prodesse, Inc.	Zusammensetzungen, Verfahren und Kits zur Detektion von Adenovirusnukleinsäuren
SG11201403756PA (en)	2012-01-01	2014-11-27	Qbi Entpr Ltd	Endo180-targeted particles for selective delivery of therapeutic and diagnostic agents
BR112014016937A2 (pt)	2012-01-12	2017-06-13	Quark Pharmaceuticals Inc	terapia de combinação para o tratamento de desordens de audição e do equilíbrio
AU2013205603B2 (en)	2012-02-01	2016-03-17	Gen-Probe Incorporated	Asymmetric hairpin target capture oligomers
WO2013123996A1 (en)	2012-02-24	2013-08-29	Astrazeneca Uk Limited	Novel sirna inhibitors of human icam-1
US9133461B2 (en)	2012-04-10	2015-09-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the ALAS1 gene
AU2013205110B2 (en)	2012-04-24	2016-10-13	Gen-Probe Incorporated	Compositions, Methods and Kits to Detect Herpes Simplex Virus Nucleic Acids
US9127274B2 (en)	2012-04-26	2015-09-08	Alnylam Pharmaceuticals, Inc.	Serpinc1 iRNA compositions and methods of use thereof
US10837014B2 (en)	2012-05-16	2020-11-17	Translate Bio Ma, Inc.	Compositions and methods for modulating SMN gene family expression
JP2015518713A (ja)	2012-05-16	2015-07-06	ラナセラピューティクスインコーポレイテッド	Ｕｔｒｎ発現を調節するための組成物及び方法
KR20150030205A (ko)	2012-05-16	2015-03-19	라나 테라퓨틱스, 인크.	Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
EA201492121A1 (ru)	2012-05-16	2015-10-30	Рана Терапьютикс, Инк.	Композиции и способы для модулирования экспрессии семейства генов гемоглобина
US20150152410A1 (en)	2012-05-16	2015-06-04	Rana Therapeutics, Inc.	Compositions and methods for modulating mecp2 expression
BR112014028644A2 (pt)	2012-05-16	2017-08-15	Rana Therapeutics Inc	Composições e métodos para modulação da expressão de atp2a2
US9994604B2 (en)	2012-05-31	2018-06-12	Bio-Lab Ltd.	Pyrazolotriazolyl nucleoside analogues and oligonucleotides comprising them
AU2013205064B2 (en)	2012-06-04	2015-07-30	Gen-Probe Incorporated	Compositions and Methods for Amplifying and Characterizing HCV Nucleic Acid
DK2885638T3 (da)	2012-07-09	2020-07-20	Sienna Cancer Diagnostics Inc	Molekylenet
AU2013205087B2 (en)	2012-07-13	2016-03-03	Gen-Probe Incorporated	Method for detecting a minority genotype
RU2693381C2 (ru)	2012-07-13	2019-07-02	Уэйв Лайф Сайенсес Лтд.	Асимметричная вспомогательная группа
WO2014012081A2 (en)	2012-07-13	2014-01-16	Ontorii, Inc.	Chiral control
BR112015000723A2 (pt)	2012-07-13	2017-06-27	Shin Nippon Biomedical Laboratories Ltd	adjuvante de ácido nucléico quiral
AU2013202793B2 (en)	2012-07-31	2014-09-18	Gen-Probe Incorporated	System, method and apparatus for automated incubation
WO2014036369A1 (en)	2012-08-30	2014-03-06	Gen-Probe Incorporated	Multiphase nucleic acid amplification
AU2013315524B2 (en)	2012-09-12	2019-01-31	Quark Pharmaceuticals, Inc.	Double-stranded oligonucleotide molecules to p53 and methods of use thereof
WO2014043291A1 (en)	2012-09-12	2014-03-20	Quark Pharmaceuticals, Inc.	Double-stranded nucleic acid compounds
ES2872349T3 (es)	2012-09-12	2021-11-02	Quark Pharmaceuticals Inc	Moléculas de oligonucleótidos bicatenarios para DDIT4 y métodos de uso de las mismas
AU2013315225B2 (en)	2012-09-14	2018-11-08	Translate Bio Ma, Inc.	Multimeric oligonucleotide compounds
AU2013205122B2 (en)	2012-10-11	2016-11-10	Gen-Probe Incorporated	Compositions and Methods for Detecting Human Papillomavirus Nucleic Acid
AU2013331434B2 (en)	2012-10-15	2019-08-08	Ionis Pharmaceuticals, Inc.	Compositions for modulating C90RF72 expression
WO2014062736A1 (en)	2012-10-15	2014-04-24	Isis Pharmaceuticals, Inc.	Methods for monitoring c9orf72 expression
HK1214830A1 (zh)	2012-11-05	2016-08-05	Foundation Medicine, Inc.	新型ntrk1融合分子及其应用
WO2014071419A2 (en)	2012-11-05	2014-05-08	Foundation Medicine, Inc.	Novel fusion molecules and uses thereof
AU2013205090B2 (en)	2012-12-07	2016-07-28	Gen-Probe Incorporated	Compositions and Methods for Detecting Gastrointestinal Pathogen Nucleic Acid
WO2014113729A2 (en)	2013-01-18	2014-07-24	Foundation Mecicine, Inc.	Methods of treating cholangiocarcinoma
EP2959000B1 (en)	2013-02-25	2018-08-15	Integrated DNA Technologies Inc.	Naphthyl-azo modifications for antisense compounds
WO2014130922A1 (en)	2013-02-25	2014-08-28	Trustees Of Boston University	Compositions and methods for treating fungal infections
JP6479759B2 (ja)	2013-03-14	2019-03-06	アーノルド, ライル, ジェイ.ARNOLD, Lyle, J.	固体支持体上での核酸増幅方法
WO2014140165A1 (en)	2013-03-14	2014-09-18	Dsm Ip Assets B.V.	Cell wall deconstruction enzymes of paecilomyces byssochlamydoides and uses thereof
MX418589B (es)	2013-03-14	2024-12-09	Alnylam Pharmaceuticals Inc	Composiciones de arni contra el componente c5 del complemento y metodos para su uso.
WO2014140167A1 (en)	2013-03-14	2014-09-18	Dsm Ip Assets B.V.	Cell wall deconstruction enzymes of malbranchea cinnamomea and uses thereof
EP2983804A4 (en)	2013-03-15	2017-03-01	Moderna Therapeutics, Inc.	Ion exchange purification of mrna
JP2016512696A (ja)	2013-03-15	2016-05-09	アーノルド, ライル, ジェイ.ARNOLD, Lyle, J.	アセンブラ配列を利用する断片化された標的核酸の増幅方法
CA2905527C (en)	2013-03-15	2023-10-03	Lyle J. Arnold	Methods for amplification of nucleic acids utilizing clamp oligonucleotides
EP2970971B1 (en)	2013-03-15	2020-09-02	Kambiz Shekdar	Genome editing using effector oligonucleotides for therapeutic treatment
CA2900852A1 (en)	2013-03-15	2014-09-18	Chromocell Corporation	Methods and materials using signaling probes
EP2971165A4 (en)	2013-03-15	2016-11-23	Moderna Therapeutics Inc	DISSOLUTION OF DNA FRAGMENTS IN MRNA MANUFACTURING METHODS
WO2014152031A1 (en)	2013-03-15	2014-09-25	Moderna Therapeutics, Inc.	Ribonucleic acid purification
WO2014152027A1 (en)	2013-03-15	2014-09-25	Moderna Therapeutics, Inc.	Manufacturing methods for production of rna transcripts
CN115261411A (zh)	2013-04-04	2022-11-01	哈佛学院校长同事会	利用CRISPR/Cas系统的基因组编辑的治疗性用途
RS60796B1 (sr)	2013-05-01	2020-10-30	Ionis Pharmaceuticals Inc	Kompozicije i postupci za modulaciju ekspresije apolipoproteina (a)
BR112015029139B1 (pt)	2013-05-22	2022-07-12	Alnylam Pharmaceuticals, Inc	Agente de rnai de fita dupla para inibição da expressão de serpina1 em uma célula, seus usos, bem como composição farmacêutica e método in vitro de inibição da expressão de serpina1 em uma célula
TWI727917B (zh)	2013-05-22	2021-05-21	美商阿尼拉製藥公司	ＴＭＰＲＳＳ６ｉＲＮＡ組成物及其使用方法
EP3004396B1 (en)	2013-06-06	2019-10-16	The General Hospital Corporation	Compositions for the treatment of cancer
RS62529B1 (sr)	2013-07-11	2021-11-30	Modernatx Inc	Kompozicije koje sadrže sintetičke polinukleotide koji kodiraju proteine povezane sa crispr i sintetičke sgrnk i postupci upotrebe
EP3027223A1 (en)	2013-07-31	2016-06-08	QBI Enterprises Ltd.	Methods of use of sphingolipid polyalkylamine oligonucleotide compounds
US9889200B2 (en)	2013-07-31	2018-02-13	Qbi Enterprises Ltd.	Sphingolipid-polyalkylamine-oligonucleotide compounds
US10053742B2 (en)	2013-08-14	2018-08-21	Gen-Probe Incorporated	Compositions and methods for detecting HEV nucleic acid
AU2014312196C1 (en) *	2013-08-28	2019-12-19	Ionis Pharmaceuticals, Inc.	Modulation of prekallikrein (PKK) expression
EP3041934A1 (en) *	2013-09-03	2016-07-13	Moderna Therapeutics, Inc.	Chimeric polynucleotides
EP2853595A1 (en)	2013-09-30	2015-04-01	Soluventis GmbH	NOTCH 1 specific siRNA molecules
MX385871B (es)	2013-10-02	2025-03-18	Alnylam Pharmaceuticals Inc	Composiciones y metodos para inhibir la expresion del gen lect2.
US10385088B2 (en)	2013-10-02	2019-08-20	Modernatx, Inc.	Polynucleotide molecules and uses thereof
UA124961C2 (uk)	2013-10-04	2021-12-22	Елнілем Фармасьютикалз, Інк.	ДВОНИТКОВА РИБОНУКЛЕЇНОВА КИСЛОТА (dsRNA) ДЛЯ ІНГІБУВАННЯ ЕКСПРЕСІЇ ALAS1
EP3052632A4 (en)	2013-10-04	2017-03-29	Rana Therapeutics, Inc.	Compositions and methods for treating amyotrophic lateral sclerosis
KR20160062069A (ko)	2013-10-11	2016-06-01	아이오니스 파마수티컬즈, 인코포레이티드	Ｃ９ｏｒｆ７２ 발현을 조절하기 위한 조성물
EP3060680B1 (en)	2013-10-21	2019-02-27	The General Hospital Corporation	Methods relating to circulating tumor cell clusters and the treatment of cancer
IL314045A (en)	2013-12-12	2024-09-01	Alnylam Pharmaceuticals Inc	Complement component irna compositions and methods of use thereof
CN106456694B (zh)	2013-12-20	2020-06-30	通用医疗公司	与循环肿瘤细胞相关的方法和测定法
EP3095460A4 (en)	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
EP3095461A4 (en)	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
WO2015108048A1 (ja)	2014-01-15	2015-07-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
PT3094728T (pt)	2014-01-16	2022-05-19	Wave Life Sciences Ltd	Desenho quiral
CN106103718B (zh)	2014-02-11	2021-04-02	阿尔尼拉姆医药品有限公司	己酮糖激酶(KHK)iRNA组合物及其使用方法
SI3137596T1 (sl) *	2014-05-01	2019-08-30	Ionis Pharmaceuticals, Inc.	Sestavki in postopki za moduliranje izražanje faktorja B komplementa
TW201607559A (zh)	2014-05-12	2016-03-01	阿尼拉製藥公司	治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
KR20250127191A (ko)	2014-05-22	2025-08-26	알닐람 파마슈티칼스 인코포레이티드	안지오텐시노겐 (ａｇｔ) ｉｒｎａ 조성물 및 이의 사용 방법
MX2016015569A (es)	2014-06-02	2017-04-25	Children´S Medical Center Corp	Metodos y composiciones para inmunomodulacion.
WO2015196128A2 (en)	2014-06-19	2015-12-23	Moderna Therapeutics, Inc.	Alternative nucleic acid molecules and uses thereof
JP2017522028A (ja)	2014-07-16	2017-08-10	モデルナティエックスインコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ．	環状ポリヌクレオチド
CN120591279A (zh)	2014-08-29	2025-09-05	儿童医疗中心有限公司	用于治疗癌症的方法和组合物
WO2016040589A1 (en)	2014-09-12	2016-03-17	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting complement component c5 and methods of use thereof
JOP20200115A1 (ar)	2014-10-10	2017-06-16	Alnylam Pharmaceuticals Inc	تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
WO2016061487A1 (en)	2014-10-17	2016-04-21	Alnylam Pharmaceuticals, Inc.	Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
EP3739062B1 (en)	2014-10-20	2023-08-16	Gen-Probe Incorporated	Red blood cell lysis solution
EP3904519A1 (en)	2014-10-30	2021-11-03	Genzyme Corporation	Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
US10858650B2 (en)	2014-10-30	2020-12-08	The General Hospital Corporation	Methods for modulating ATRX-dependent gene repression
JOP20200092A1 (ar)	2014-11-10	2017-06-16	Alnylam Pharmaceuticals Inc	تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
CN107250362B (zh)	2014-11-17	2021-10-22	阿尔尼拉姆医药品有限公司	载脂蛋白C3(APOC3)iRNA组合物及其使用方法
WO2016083624A1 (en)	2014-11-28	2016-06-02	Silence Therapeutics Gmbh	Means for inhibiting the expression of edn1
CN107428821B (zh)	2014-12-08	2022-06-24	博格有限责任公司	包括细丝蛋白a的标志物在诊断和治疗前列腺癌中的用途
JP6944873B2 (ja)	2015-01-09	2021-10-06	ジェン−プローブ・インコーポレーテッド	細菌性膣症を診断するための方法および組成物
EP3256591A4 (en)	2015-02-13	2018-08-08	Translate Bio Ma, Inc.	Hybrid oligonucleotides and uses thereof
CA2976445A1 (en)	2015-02-13	2016-08-18	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2016149357A1 (en)	2015-03-16	2016-09-22	Gen-Probe Incorporated	Methods and compositions for detecting bacterial nucleic acid and diagnosing bacterial vaginosis
US10900036B2 (en)	2015-03-17	2021-01-26	The General Hospital Corporation	RNA interactome of polycomb repressive complex 1 (PRC1)
WO2016160721A1 (en)	2015-03-27	2016-10-06	President And Fellows Of Harvard College	Modified t cells and methods of making and using the same
MX2017012610A (es)	2015-04-08	2018-03-16	Alnylam Pharmaceuticals Inc	Composiciones y metodos para inhibir la expresion del gen lect2.
AU2016249002B2 (en)	2015-04-16	2019-07-18	Ionis Pharmaceuticals, Inc.	Compositions for modulating C90RF72 expression
WO2016201301A1 (en)	2015-06-12	2016-12-15	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions and methods of use thereof
WO2016205323A1 (en)	2015-06-18	2016-12-22	Alnylam Pharmaceuticals, Inc.	Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en)	2015-06-23	2016-12-29	Alnylam Pharmaceuticals, Inc.	Glucokinase (gck) irna compositions and methods of use thereof
WO2017011286A1 (en)	2015-07-10	2017-01-19	Alnylam Pharmaceuticals, Inc.	Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
MA43072A (fr)	2015-07-22	2018-05-30	Wave Life Sciences Ltd	Compositions d'oligonucléotides et procédés associés
WO2017040078A1 (en)	2015-09-02	2017-03-09	Alnylam Pharmaceuticals, Inc.	PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
PL3350333T3 (pl)	2015-09-17	2022-03-07	Modernatx, Inc.	Polinukleotydy zawierające region stabilizujący ogon
US11434486B2 (en)	2015-09-17	2022-09-06	Modernatx, Inc.	Polynucleotides containing a morpholino linker
WO2017075038A1 (en)	2015-10-26	2017-05-04	Rana Therapeutics, Inc.	Nanoparticle formulations for delivery of nucleic acid complexes
US11260073B2 (en)	2015-11-02	2022-03-01	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating C90RF72
KR20230119027A (ko)	2015-12-07	2023-08-14	젠자임 코포레이션	Serpinc1-연관 장애의 치료를 위한 방법 및 조성물
US11111549B2 (en)	2016-01-04	2021-09-07	Gen-Probe Incorporated	Methods and compositions for detecting Candida species
EP3228326A1 (en)	2016-04-05	2017-10-11	Silence Therapeutics GmbH	Nucleic acid linked to a trivalent glycoconjugate
US11365415B2 (en)	2016-04-14	2022-06-21	University Of Florida Research Foundation, Inc.	Use of miR-223-3p as a cancer therapeutic and method for treating cancer using the same
MA45295A (fr)	2016-04-19	2019-02-27	Alnylam Pharmaceuticals Inc	Composition d'arni de protéine de liaison de lipoprotéines haute densité (hdlbp/vigiline) et procédés pour les utiliser
EP3449002A4 (en)	2016-04-29	2019-09-25	Nanyang Technological University	G-QUADRUPLEX-CONTAINING ANTISENSE OLIGONUCLEOTIDES
WO2017214518A1 (en)	2016-06-10	2017-12-14	Alnylam Pharmaceuticals, Inc.	COMPLETMENT COMPONENT C5 iRNA COMPOSTIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
WO2017223176A1 (en)	2016-06-24	2017-12-28	Modernatx, Inc.	Methods and apparatus for filtration
CN109863252B (zh)	2016-10-19	2024-09-20	简·探针公司	用于检测或定量丙型肝炎病毒的组合物和方法
EP3541959A1 (en)	2016-11-21	2019-09-25	Gen-Probe Incorporated	Compositions and methods for detecting or quantifying hepatitis b virus
SG10201913552UA (en)	2016-12-16	2020-03-30	Alnylam Pharmaceuticals Inc	Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
TWI851534B (zh)	2016-12-22	2024-08-11	美商英特利亞醫療公司	用於治療α-１抗胰蛋白酶缺乏症之組合物及方法
EP4212634A1 (en)	2017-03-24	2023-07-19	Gen-Probe Incorporated	Compositions and methods for detection of flu b in samples
WO2018175883A1 (en)	2017-03-24	2018-09-27	Gen-Probe Incorporated	Compositions and methods for detecting or quantifying parainfluenza virus
EP3601618B1 (en)	2017-03-25	2024-09-04	Gen-Probe Incorporated	Compositions, methods and kits to detect adenovirus, metapneumovirus and/or rhinovirus nucleic acids
WO2018185253A1 (en)	2017-04-05	2018-10-11	Silence Therapeutics Gmbh	Ligand modified double-stranded nucleic acids
WO2018185252A1 (en)	2017-04-05	2018-10-11	Silence Therapeutics Gmbh	Nucleic acid conjugates
EP3385272A1 (en)	2017-04-05	2018-10-10	Silence Therapeutics GmbH	Further novel oligonucleotide-ligand conjugates
MY205546A (en)	2017-04-18	2024-10-25	Alnylam Pharmaceuticals Inc	Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
EP3622083A1 (en)	2017-05-11	2020-03-18	Gen-Probe Incorporated	Compositions and methods for isolating target nucleic acids
WO2018226798A1 (en)	2017-06-07	2018-12-13	Gen-Probe Incorporated	Detecting babesia species nucleic acid in a sample
EP4286055B1 (en)	2017-07-10	2025-03-19	Gen-Probe Incorporated	Method for determining the presence of multiple forms of a nucleic acid analyte in a sample
EP3651852A1 (en)	2017-07-10	2020-05-20	Genzyme Corporation	Methods and compositions for treating a bleeding event in a subject having hemophilia
AU2018301477A1 (en)	2017-07-13	2020-02-27	Alnylam Pharmaceuticals Inc.	Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof
CA3072452A1 (en)	2017-08-11	2019-02-14	Gen-Probe Incorporated	Compositions and methods for detecting staphylococcus aureus
KR20250093420A (ko)	2017-09-29	2025-06-24	인텔리아 테라퓨틱스, 인크.	게놈 편집을 위한 폴리뉴클레오티드, 조성물 및 방법
SG11202002565YA (en)	2017-09-29	2020-04-29	Intellia Therapeutics Inc	Compositions and methods for ttr gene editing and treating attr amyloidosis
CA3078971A1 (en)	2017-11-01	2019-05-09	Alnylam Pharmaceuticals, Inc.	Complement component c3 irna compositions and methods of use thereof
EP3710587A1 (en)	2017-11-16	2020-09-23	Alnylam Pharmaceuticals, Inc.	Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
CN111465707A (zh)	2017-11-17	2020-07-28	简·探针公司	用于检测C1orf43核酸的组合物和方法
WO2019100039A1 (en)	2017-11-20	2019-05-23	Alnylam Pharmaceuticals, Inc.	Serum amyloid p component (apcs) irna compositions and methods of use thereof
WO2019118550A1 (en)	2017-12-13	2019-06-20	Gen-Probe Incorporated	Methods for biological sample processing
WO2019118735A1 (en)	2017-12-15	2019-06-20	Gen-Probe Incorporated	Compositions and methods for detecting toxigenic clostridium difficile
AU2018388484A1 (en)	2017-12-18	2020-07-30	Alnylam Pharmaceuticals, Inc.	High mobility group box-1 (HMGB1) iRNA compositions and methods of use thereof
JP2021512303A (ja)	2018-01-29	2021-05-13	ジェン−プローブ・インコーポレーテッド	分析システムおよび方法
EP4461817A3 (en)	2018-02-06	2025-01-22	Gen-Probe Incorporated	Far-red dye probe formulations
WO2019183570A1 (en)	2018-03-22	2019-09-26	Board Of Regents, The University Of Texas System	Soluble interleukin-7 receptor (sil7r) molulating therapy to treat autoimmune diseases and cancer
EP3549610A1 (en)	2018-04-05	2019-10-09	Silence Therapeutics GmbH	Nucleic acid conjugates
TWI851574B (zh)	2018-05-14	2024-08-11	美商阿尼拉製藥公司	血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
GB2597567B (en)	2018-06-13	2022-11-23	Gen Probe Inc	Compositions and methods for detecting group B streptococcus nucleic acid
CA3105684A1 (en)	2018-07-10	2020-01-16	Gen-Probe Incorporated	Methods and systems for detecting and quantifying nucleic acids
WO2020028327A1 (en)	2018-07-31	2020-02-06	Intellia Therapeutics, Inc.	Compositions and methods for hydroxyacid oxidase 1 ( hao1) gene editing for treating primary hyperoxaluria type 1 (ph1)
AU2019314449B2 (en)	2018-08-01	2026-01-08	Gen-Probe Incorporated	Compositions and methods for detecting nucleic acids of Epstein-Barr virus
EP3841223A1 (en)	2018-08-08	2021-06-30	Gen-Probe Incorporated	Compositions, methods and kits for detecting mycoplasma genitalium
TW202023574A (zh)	2018-08-13	2020-07-01	美商阿尼拉製藥公司	Ｂ型肝炎病毒（ＨＢＶ）ｄｓＲＮＡ劑組合物及其使用方法
EP3837367A1 (en)	2018-08-16	2021-06-23	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the lect2 gene
EP3841224A1 (en)	2018-08-21	2021-06-30	Gen-Probe Incorporated	Compositions and methods for amplifying, detecting or quantifying human cytomegalovirus
JP7389111B2 (ja)	2018-08-24	2023-11-29	ジェン－プローブ・インコーポレーテッド	細菌の核酸を検出し、細菌性膣炎を診断するための組成物および方法
EP3853364A1 (en)	2018-09-18	2021-07-28	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
AU2019350777B2 (en)	2018-09-27	2025-11-27	Gen-Probe Incorporated	Compositions and methods for detecting Bordetella pertussis and Bordetellaparapertussis nucleic acid
MX2021003457A (es)	2018-09-28	2021-07-16	Intellia Therapeutics Inc	Composiciones y métodos para la edición génica de lactato deshidrogenasa (ldha).
JP2022512703A (ja)	2018-10-16	2022-02-07	インテリアセラピューティクス，インコーポレイテッド	免疫療法のための組成物および方法
EP3867378A1 (en)	2018-10-18	2021-08-25	Intellia Therapeutics, Inc.	Compositions and methods for treating alpha-1 antitrypsin deficiencey
JP7578590B2 (ja)	2018-10-18	2024-11-06	インテリアセラピューティクス，インコーポレーテッド	第ｉｘ因子を発現するための組成物及び方法
EP4667576A2 (en)	2018-10-18	2025-12-24	Intellia Therapeutics, Inc.	Nucleic acid constructs and methods of use
KR20210102883A (ko)	2018-10-18	2021-08-20	인텔리아 테라퓨틱스, 인크.	알부민 좌위로부터 트랜스진을 발현하기 위한 조성물 및 방법
CN113195743A (zh)	2018-10-22	2021-07-30	简·探针公司	扩增，检测或定量人类多瘤病毒bk病毒的组合物和方法
US10913951B2 (en)	2018-10-31	2021-02-09	University of Pittsburgh—of the Commonwealth System of Higher Education	Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
WO2020117706A1 (en)	2018-12-03	2020-06-11	Triplet Therapeutics, Inc.	Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
WO2020132521A1 (en)	2018-12-20	2020-06-25	Praxis Precision Medicines, Inc.	Compositions and methods for the treatment of kcnt1 related disorders
TW202030333A (zh)	2018-12-20	2020-08-16	美商簡探針公司	用於檢測瘧原蟲物種核酸之組成物及方法
MY206794A (en)	2018-12-20	2025-01-08	Humabs Biomed Sa	Combination hbv therapy
TW202043471A (zh)	2019-01-16	2020-12-01	美商健贊公司	ＳＥＲＰＩＮＣ１ｉＲＮＡ組成物及其使用方法
EP4407046A3 (en)	2019-03-22	2024-10-16	Gen-Probe Incorporated	Compositions and methods for detecting group a streptococcus
KR20220004984A (ko)	2019-03-28	2022-01-12	인텔리아 테라퓨틱스, 인크.	Ttr 유전자 편집을 위한 조성물 및 방법 및 코르티코스테로이드를 포함하는 attr 아밀로이드증의 치료 또는 그의 용도
MX2021011565A (es)	2019-03-28	2021-11-12	Intellia Therapeutics Inc	Composiciones y métodos que comprenden un arn guía de ttr y un polinucleótido que codifica un agente de fijacion a adn guiado por arn.
WO2020198641A2 (en)	2019-03-28	2020-10-01	Intellia Therapeutics, Inc.	Polynucleotides, compositions, and methods for polypeptide expression
US20200377951A1 (en)	2019-04-30	2020-12-03	Chondrial Therapeutics, Inc.	Frataxin-sensitive markers for determining effectiveness of frataxin replacement therapy
US12210028B2 (en)	2019-05-03	2025-01-28	Gen-Probe Incorporated	Receptacle delivery system
KR20220036914A (ko)	2019-05-13	2022-03-23	비르 바이오테크놀로지, 인코포레이티드	B형 간염 바이러스(hbv) 감염을 치료하기 위한 조성물 및 방법
CN114096683A (zh)	2019-07-03	2022-02-25	简·探针公司	用于确定样品中阴道毛滴虫的存在的寡核苷酸
WO2021022108A2 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021022109A1 (en)	2019-08-01	2021-02-04	Alnylam Pharmaceuticals, Inc.	SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021030522A1 (en)	2019-08-13	2021-02-18	Alnylam Pharmaceuticals, Inc.	SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
US20220298548A1 (en)	2019-08-23	2022-09-22	Gen-Probe Incorporated	Compositions, methods and kits for detecting treponema pallidum
EP4022057A1 (en)	2019-08-27	2022-07-06	Vertex Pharmaceuticals Incorporated	Compositions and methods for treatment of disorders associated with repetitive dna
AU2020343255A1 (en)	2019-09-03	2022-03-24	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting expression of the LECT2 gene
EP4025715A1 (en)	2019-09-05	2022-07-13	Gen-Probe Incorporated	Detection of chlamydia trachomatis nucleic acid variants
US12503699B2 (en)	2019-10-04	2025-12-23	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing UGT1a1 gene expression
EP4045652A1 (en)	2019-10-18	2022-08-24	Alnylam Pharmaceuticals, Inc.	Solute carrier family member irna compositions and methods of use thereof
JP7676377B2 (ja)	2019-10-22	2025-05-14	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体成分Ｃ３ｉＲＮＡ組成物およびその使用方法
WO2021087325A1 (en)	2019-11-01	2021-05-06	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing dnajb1-prkaca fusion gene expression
TW202132567A (zh)	2019-11-01	2021-09-01	美商阿尼拉製藥公司	亨汀頓蛋白（ＨＴＴ）ｉＲＮＡ劑組成物及其使用方法
WO2021096763A1 (en)	2019-11-13	2021-05-20	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
WO2021097358A1 (en)	2019-11-14	2021-05-20	Gen-Probe Incorporated	Compositions and methods for capturing target nucleic acids
EP4061945A1 (en)	2019-11-22	2022-09-28	Alnylam Pharmaceuticals, Inc.	Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
EP4073251A1 (en)	2019-12-13	2022-10-19	Alnylam Pharmaceuticals, Inc.	Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
WO2021126734A1 (en)	2019-12-16	2021-06-24	Alnylam Pharmaceuticals, Inc.	Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
CN115349019A (zh)	2020-01-16	2022-11-15	Dnae诊断有限公司	用于分离靶多核苷酸的组合物、试剂盒和方法
WO2021154941A1 (en)	2020-01-31	2021-08-05	Alnylam Pharmaceuticals, Inc.	Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
AU2021212195A1 (en)	2020-01-31	2022-09-15	Regeneron Pharmaceuticals, Inc.	Use of liquid chromatography and mass spectrometry to characterize oligonucleotides
EP4100528A1 (en)	2020-02-07	2022-12-14	Intellia Therapeutics, Inc.	Compositions and methods for kallikrein (klkb1) gene editing
MX2022009763A (es)	2020-02-10	2022-09-09	Alnylam Pharmaceuticals Inc	Composiciones y metodos para silenciar la expresion del factor de crecimiento endotelial vascular a (vegf-a).
CN115397989A (zh)	2020-02-18	2022-11-25	阿尔尼拉姆医药品有限公司	载脂蛋白C3(APOC3)iRNA组合物及其使用方法
WO2021174031A2 (en) *	2020-02-28	2021-09-02	Ionis Pharmaceuticals, Inc.	Compounds and methods for modulating splicing of pre-mrna
WO2021178607A1 (en)	2020-03-05	2021-09-10	Alnylam Pharmaceuticals, Inc.	Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
CA3174725A1 (en)	2020-03-06	2021-09-10	Alnylam Pharmaceuticals, Inc.	Ketohexokinase (khk) irna compositions and methods of use thereof
WO2021188611A1 (en)	2020-03-18	2021-09-23	Alnylam Pharmaceuticals, Inc.	Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
WO2021195307A1 (en)	2020-03-26	2021-09-30	Alnylam Pharmaceuticals, Inc.	Coronavirus irna compositions and methods of use thereof
WO2021202443A2 (en)	2020-03-30	2021-10-07	Alnylam Pharmaceucticals, Inc.	Compositions and methods for silencing dnajc15 gene expression
MX2022012493A (es)	2020-04-06	2022-10-27	Alnylam Pharmaceuticals Inc	Composiciones y metodos para el silenciamiento de la expresion de miocilina (myoc).
WO2021206922A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
US20230159933A1 (en)	2020-04-07	2023-05-25	Alnylam Pharmaceuticals, Inc.	Compositions and methods for silencing scn9a expression
WO2021206917A1 (en)	2020-04-07	2021-10-14	Alnylam Pharmaceuticals, Inc.	ANGIOTENSIN-CONVERTING ENZYME 2 (ACE2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP4143319A1 (en)	2020-04-27	2023-03-08	Alnylam Pharmaceuticals, Inc.	Apolipoprotein e (apoe) irna agent compositions and methods of use thereof
KR20230017783A (ko)	2020-04-28	2023-02-06	인텔리아 테라퓨틱스, 인크.	시험관내 세포 전달 방법
KR20230017789A (ko)	2020-04-30	2023-02-06	알닐람 파마슈티칼스 인코포레이티드	보체 인자 B (CFB) iRNA 조성물 및 이의 사용 방법
EP4146821A1 (en)	2020-05-07	2023-03-15	Grifols Diagnostic Solutions Inc.	Methods and compositions for detecting sars-cov-2 nucleic acid
EP4150089A1 (en)	2020-05-15	2023-03-22	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
EP4150076A1 (en)	2020-05-15	2023-03-22	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
WO2021231685A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
WO2021231675A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
EP4150090A1 (en)	2020-05-15	2023-03-22	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of otoferlin (otof)
WO2021231679A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
WO2021231698A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
WO2021231673A1 (en)	2020-05-15	2021-11-18	Korro Bio, Inc.	Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
US20230183707A1 (en)	2020-05-21	2023-06-15	Alnylam Pharmaceuticals, Inc.	Compositions and methods for inhibiting marc1 gene expression
CN115885042A (zh)	2020-05-22	2023-03-31	波涛生命科学有限公司	双链寡核苷酸组合物及其相关方法
AR122534A1 (es)	2020-06-03	2022-09-21	Triplet Therapeutics Inc	Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
EP4649951A2 (en)	2020-06-09	2025-11-19	Alnylam Pharmaceuticals, Inc.	Sirna compositions and methods for silencing gpam (glycerol-3-phosphate acyltransferase 1, mitochondrial) expression
EP3922720A1 (en)	2020-06-09	2021-12-15	Universidad de Murcia	Therapy to prevent adverse cardiac remodeling following an acute myocardial infarction
WO2021252557A1 (en)	2020-06-09	2021-12-16	Alnylam Pharmaceuticals, Inc.	Rnai compositions and methods of use thereof for delivery by inhalation
AU2021292296A1 (en)	2020-06-18	2023-01-19	Alnylam Pharmaceuticals, Inc.	Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof
EP4171747A1 (en)	2020-06-24	2023-05-03	VIR Biotechnology, Inc.	Engineered hepatitis b virus neutralizing antibodies and uses thereof
EP4182482A1 (en)	2020-07-17	2023-05-24	Gen-Probe Incorporated	Detection of macrolide-resistant mycoplasma genitalium
WO2022047359A1 (en)	2020-08-31	2022-03-03	Berg Llc	Protein biomarkers for pancreatic cancer
US20220096606A1 (en)	2020-09-09	2022-03-31	Vertex Pharmaceuticals Incorporated	Compositions and Methods for Treatment of Duchenne Muscular Dystrophy
EP4217489A1 (en)	2020-09-24	2023-08-02	Alnylam Pharmaceuticals, Inc.	Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
TW202229552A (zh)	2020-10-05	2022-08-01	美商艾拉倫製藥股份有限公司	Ｇ蛋白－偶合受體７５（ＧＰＲ７５）ｉＲＮＡ組成物及其使用方法
JP7584643B2 (ja)	2020-10-21	2024-11-15	ジェン－プローブ・インコーポレーテッド	流体コンテナ管理システム
CA3198823A1 (en)	2020-10-21	2022-04-28	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating primary hyperoxaluria
WO2022087329A1 (en)	2020-10-23	2022-04-28	Alnylam Pharmaceuticals, Inc.	Mucin 5b (muc5b) irna compositions and methods of use thereof
EP4240854A1 (en)	2020-11-06	2023-09-13	Vertex Pharmaceuticals Incorporated	Compositions and methods for treatment of dm1 with slucas9 and sacas9
IL302709A (en)	2020-11-13	2023-07-01	Alnylam Pharmaceuticals Inc	Coagulation factor iRNA compositions (F5) and methods of using them
EP4256053A1 (en)	2020-12-01	2023-10-11	Alnylam Pharmaceuticals, Inc.	Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
EP4259795A1 (en)	2020-12-08	2023-10-18	Alnylam Pharmaceuticals, Inc.	Coagulation factor x (f10) irna compositions and methods of use thereof
AU2021394998A1 (en)	2020-12-11	2023-06-29	Intellia Therapeutics, Inc.	Polynucleotides, compositions, and methods for genome editing involving deamination
MX2023006878A (es)	2020-12-11	2023-07-31	Intellia Therapeutics Inc	Composiciones y métodos para reducir el mhc de clase ii en una célula.
TW202242101A (zh)	2020-12-23	2022-11-01	美商英特利亞醫療公司	用於細胞中基因修飾ciita之組合物及方法
CR20230320A (es)	2020-12-23	2023-10-23	Intellia Therapeutics Inc	Composiciones y métodos para reducir los hla-a en una célula
IL303886A (en)	2020-12-23	2023-08-01	Flagship Pioneering Inc	Compositions of modified trems and uses thereof
JP2024502036A (ja)	2020-12-30	2024-01-17	インテリアセラピューティクス，インコーポレイテッド	操作されたｔ細胞
WO2022150260A1 (en)	2021-01-05	2022-07-14	Alnylam Pharmaceuticals, Inc.	COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2022155521A1 (en)	2021-01-15	2022-07-21	Board Of Regents, The University Of Texas System	A trans-complementation system for sars-cov-2
CN117098840A (zh)	2021-02-08	2023-11-21	因特利亚治疗公司	用于免疫疗法的自然杀伤细胞受体2b4组合物和方法
CN117042794A (zh)	2021-02-08	2023-11-10	因特利亚治疗公司	用于免疫疗法的t细胞免疫球蛋白和粘蛋白结构域3(tim3)组合物和方法
CN117042793A (zh)	2021-02-08	2023-11-10	因特利亚治疗公司	用于免疫疗法的淋巴细胞活化基因3(lag3)组合物和方法
IL304880A (en)	2021-02-12	2023-10-01	Alnylam Pharmaceuticals Inc	Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
EP4298220A1 (en)	2021-02-25	2024-01-03	Alnylam Pharmaceuticals, Inc.	Prion protein (prnp) irna compositions and methods of use thereof
WO2022182959A1 (en)	2021-02-26	2022-09-01	Vertex Pharmaceuticals Incorporated	Compositions and methods for treatment of myotonic dystrophy type 1 with crispr/slucas9
BR112023016645A2 (pt)	2021-02-26	2023-11-14	Alnylam Pharmaceuticals Inc	Composições de irna de ceto-hexoquinase (khk) e métodos de uso das mesmas
TW202302848A (zh)	2021-02-26	2023-01-16	美商維泰克斯製藥公司	以crispr/sacas9治療第1型肌強直性營養不良之組合物及方法
TW202302849A (zh)	2021-03-04	2023-01-16	美商艾拉倫製藥股份有限公司	類血管生成素３（ＡＮＧＰＴＬ３）ｉＲＮＡ組成物及其使用方法
EP4305169A1 (en)	2021-03-12	2024-01-17	Alnylam Pharmaceuticals, Inc.	Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
JP2024510996A (ja)	2021-03-15	2024-03-12	ジェン－プローブ・インコーポレーテッド	生物学的サンプル処理のための組成物および方法
US20240165271A1 (en)	2021-03-26	2024-05-23	The Board Of Regents Of The University Of Texas System	Nucleotide editing to reframe dmd transcripts by base editing and prime editing
IL307239A (en)	2021-03-29	2023-11-01	Alnylam Pharmaceuticals Inc	Preparations containing Huntingtin IRNA factor (HTT) and methods of using them
EP4314293A1 (en)	2021-04-01	2024-02-07	Alnylam Pharmaceuticals, Inc.	Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
WO2022216846A1 (en)	2021-04-06	2022-10-13	Berg Llc	Protein markers for estrogen receptor (er)-positive-like and estrogen receptor (er)-negative-like breast cancer
IL307530A (en)	2021-04-06	2023-12-01	Bpgbio Inc	Protein markers for estrogen receptor (er)-positive luminal a(la)-like and luminal b1 (lb1)-like breast cancer
IL307528A (en)	2021-04-06	2023-12-01	Bpgbio Inc	Protein markers for the prognosis of breast cancer progression
IL307926A (en)	2021-04-26	2023-12-01	Alnylam Pharmaceuticals Inc	Transmembrane assemblies, serine 6 ((TMPRSS6 IRNA) and methods of using them
WO2022229851A1 (en)	2021-04-26	2022-11-03	Crispr Therapeutics Ag	Compositions and methods for using slucas9 scaffold sequences
WO2022232343A1 (en)	2021-04-29	2022-11-03	Alnylam Pharmaceuticals, Inc.	Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
WO2022234519A1 (en)	2021-05-05	2022-11-10	Crispr Therapeutics Ag	Compositions and methods for using sacas9 scaffold sequences
WO2022245583A1 (en)	2021-05-18	2022-11-24	Alnylam Pharmaceuticals, Inc.	Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
US20240263177A1 (en)	2021-05-20	2024-08-08	Korro Bio, Inc.	Methods and Compositions for Adar-Mediated Editing
WO2022256283A2 (en)	2021-06-01	2022-12-08	Korro Bio, Inc.	Methods for restoring protein function using adar
TW202317762A (zh)	2021-06-02	2023-05-01	美商艾拉倫製藥股份有限公司	含有類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）的ｉＲＮＡ組成物及其使用方法
WO2022256290A2 (en)	2021-06-04	2022-12-08	Alnylam Pharmaceuticals, Inc.	HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
AR126070A1 (es)	2021-06-08	2023-09-06	Alnylam Pharmaceuticals Inc	Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4)
JP2024527525A (ja)	2021-06-22	2024-07-25	インテリアセラピューティクス，インコーポレイテッド	肝遺伝子のインビボ編集のための方法
EP4363574A1 (en)	2021-06-29	2024-05-08	Korro Bio, Inc.	Methods and compositions for adar-mediated editing
US20230194709A9 (en)	2021-06-29	2023-06-22	Seagate Technology Llc	Range information detection using coherent pulse sets with selected waveform characteristics
CA3225469A1 (en)	2021-06-30	2023-01-05	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
WO2023003805A1 (en)	2021-07-19	2023-01-26	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
CA3226451A1 (en)	2021-07-21	2023-01-26	Sam Reed	Method and system comprising a cartridge for sequencing target polynucleotides
GB202110485D0 (en)	2021-07-21	2021-09-01	Dnae Diagnostics Ltd	Compositions, kits and methods for sequencing target polynucleotides
GB202110479D0 (en)	2021-07-21	2021-09-01	Dnae Diagnostics Ltd	Compositions, kits and methods for sequencing target polynucleotides
MX2024000863A (es)	2021-07-23	2024-02-09	Alnylam Pharmaceuticals Inc	Composiciones de arni de beta-catenina (ctnnb1) y metodos de uso de estas.
EP4382623A3 (en)	2021-07-27	2024-10-16	Gen-Probe Incorporated	Compositions and methods for detecting stec and at least one of salmonella, c. jejuni, c. coli, and shigella
JP2024529437A (ja)	2021-07-29	2024-08-06	アルナイラムファーマシューティカルズ，インコーポレイテッド	３－ヒドロキシ－３－メチルグリタル－ＣＯＡレダクターゼ（ＨＭＧＣＲ）ｉＲＮＡ組成物およびその使用方法
MX2024001194A (es)	2021-08-03	2024-02-27	Alnylam Pharmaceuticals Inc	Composiciones de acido ribonucleico de interferencia (arni) de transtiretina (ttr) y sus metodos de uso.
CA3228255A1 (en)	2021-08-04	2023-02-09	Alnylam Pharmaceuticals, Inc.	Irna compositions and methods for silencing angiotensinogen (agt)
WO2023018637A1 (en)	2021-08-09	2023-02-16	Vertex Pharmaceuticals Incorporated	Gene editing of regulatory elements
BR112024001923A2 (pt)	2021-08-13	2024-04-30	Alnylam Pharmaceuticals Inc	Composições de irna de fator xii (f12) e métodos de usos das mesmas
WO2023028471A1 (en)	2021-08-24	2023-03-02	Intellia Therapeutics, Inc.	Programmed cell death protein 1 (pd1) compositions and methods for cell-based therapy
MX2024002440A (es)	2021-08-31	2024-03-08	Alnylam Pharmaceuticals Inc	Composiciones de acido ribonucleico de interferencia (arni) del efector b similar al factor de fragmentacion de adn subunidad alfa (dffa) que induce la muerte celular (cideb) y metodos de uso de estas.
EP4399302A2 (en)	2021-09-08	2024-07-17	Vertex Pharmaceuticals Incorporated	Precise excisions of portions of exon 51 for treatment of duchenne muscular dystrophy
JP2024535850A (ja)	2021-09-17	2024-10-02	アルナイラムファーマシューティカルズ，インコーポレイテッド	補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
AU2022345881A1 (en)	2021-09-20	2024-03-21	Alnylam Pharmaceuticals, Inc.	Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
US20230193406A1 (en)	2021-09-22	2023-06-22	Herbalife International Of America, Inc.	Methods and compositions for processing botanical materials
MX2024003519A (es)	2021-09-24	2024-04-01	Alnylam Pharmaceuticals Inc	Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
AU2022370009A1 (en)	2021-10-22	2024-05-16	Korro Bio, Inc.	Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
WO2023076450A2 (en)	2021-10-29	2023-05-04	Alnylam Pharmaceuticals, Inc.	HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
MX2024004750A (es)	2021-10-29	2024-05-13	Alnylam Pharmaceuticals Inc	Composiciones de acido ribonucleico de interferencia (arni) contra el factor b del complemento (cfb) y sus metodos de uso.
MX2024005242A (es)	2021-11-03	2024-07-02	Intellia Therapeutics Inc	Polinucleotidos, composiciones y metodos para la edicion del genoma.
CN118369110A (zh)	2021-11-03	2024-07-19	英特利亚治疗股份有限公司	用于免疫疗法的cd38组合物和方法
EP4469575A2 (en)	2022-01-24	2024-12-04	Alnylam Pharmaceuticals, Inc.	Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
WO2023172926A1 (en)	2022-03-08	2023-09-14	Vertex Pharmaceuticals Incorporated	Precise excisions of portions of exons for treatment of duchenne muscular dystrophy
TW202345911A (zh)	2022-03-08	2023-12-01	美商維泰克斯製藥公司	用於治療杜興氏肌肉失養症(duchenne muscular dystrophy)之部分外顯子44、50及53之精確切除
EP4499829A2 (en)	2022-03-29	2025-02-05	Accuredit Therapeutics (Suzhou) Co., Ltd.	Compositions and methods for treatment of transthyretin amyloidosis
WO2023196937A1 (en)	2022-04-06	2023-10-12	Larimar Therapeutics, Inc.	Frataxin-sensitive markers for monitoring frataxin replacement therapy
EP4511485A1 (en)	2022-04-18	2025-02-26	Vertex Pharmaceuticals Incorporated	Compositions and methods for enhancing aav therapy and decreasing tropism of aav to the liver
US20250268940A1 (en)	2022-04-19	2025-08-28	Intellia Therapeutics, Inc.	Chimeric antigen receptor compositions and uses
WO2023240201A1 (en)	2022-06-08	2023-12-14	Larimar Therapeutics, Inc.	Frataxin-sensitive markers for monitoring progression and treatment of leigh syndrome
TW202413631A (zh)	2022-06-16	2024-04-01	美商英特利亞醫療公司	用於基因體編輯之組成物及方法
JP2025520366A (ja)	2022-06-16	2025-07-03	インテリアセラピューティクス，インコーポレイテッド	細胞内のｍｈｃクラスｉを低減する組成物及び方法
TW202408595A (zh)	2022-06-16	2024-03-01	美商英特利亞醫療公司	用於對細胞進行遺傳修飾之方法及組合物
JP2025525437A (ja)	2022-06-29	2025-08-05	インテリアセラピューティクス，インコーポレイテッド	操作されたｔ細胞
EP4558634A1 (en)	2022-07-18	2025-05-28	Vertex Pharmaceuticals Incorporated	Tandem guide rnas (tg-rnas) and their use in genome editing
KR20250054842A (ko)	2022-07-29	2025-04-23	리제너론 파마슈티칼스 인코포레이티드	뇌 및 근육으로의 트랜스페린 수용체(tfr)-매개 전달을 위한 조성물 및 방법
JP2025527531A (ja)	2022-08-18	2025-08-22	アルナイラムファーマシューティカルズ，インコーポレイテッド	ユニバーサル非標的ｓｉｒｎａ組成物およびその使用方法
WO2024054924A1 (en)	2022-09-08	2024-03-14	Gen-Probe Incorporated	Method of detecting nucleic acid analytes using dual-specificity primers
JP2025532593A (ja)	2022-09-15	2025-10-01	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	１７ｂ－ヒドロキシステロイドデヒドロゲナーゼ１３型（ｈｓｄ１７ｂ１３）ｉｒｎａ組成物およびその使用方法
EP4590820A2 (en)	2022-09-22	2025-07-30	Accuredit Therapeutics (Suzhou) Co., Ltd.	Compositions and methods for treatment of hypercholesterolemia and/or cardiovascular disease
EP4612184A1 (en)	2022-11-04	2025-09-10	Regeneron Pharmaceuticals, Inc.	Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle
EP4615517A1 (en)	2022-11-08	2025-09-17	Orna Therapeutics, Inc.	Circular rna compositions
WO2024107765A2 (en)	2022-11-14	2024-05-23	Regeneron Pharmaceuticals, Inc.	Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
CN120322555A (zh)	2022-12-21	2025-07-15	因特利亚治疗公司	用于前蛋白转化酶枯草杆菌蛋白酶kexin 9(pcsk9)编辑的组合物和方法
CN120641573A (zh)	2022-12-22	2025-09-12	英特利亚治疗股份有限公司	用于分析脂质核酸组装体的核酸运载物的方法
TW202428878A (zh)	2022-12-23	2024-07-16	美商英特利亞醫療公司	用於基因體編輯之系統及方法
WO2024161179A1 (en)	2023-01-31	2024-08-08	Mobidiag Oy	Compositions and methods for detecting stx nucleic acids
TW202449152A (zh)	2023-02-09	2024-12-16	美商艾拉倫製藥股份有限公司	Ｒｅｖｅｒｓｉｒ分子及其使用方法
TW202436622A (zh)	2023-03-06	2024-09-16	美商英特利亞醫療公司	用於ｂ型肝炎病毒（ｈｂｖ）基因體編輯之組合物及方法
WO2024186971A1 (en)	2023-03-07	2024-09-12	Intellia Therapeutics, Inc.	Cish compositions and methods for immunotherapy
WO2024220373A1 (en)	2023-04-15	2024-10-24	Accent Therapeutics, Inc.	Assays for monitoring inhibition of rna helicase dhx9
WO2024220746A2 (en)	2023-04-21	2024-10-24	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting fatty acid synthase and related methods
EP4454758A1 (en)	2023-04-28	2024-10-30	Mobidiag Oy	Nucleic acid amplification process controls
EP4455303A1 (en)	2023-04-28	2024-10-30	Mobidiag Oy	Nucleic acid amplification process controls
EP4455304A1 (en)	2023-04-28	2024-10-30	Mobidiag Oy	Nucleic acid amplification process controls
AU2024269222A1 (en)	2023-05-05	2025-10-09	Orna Therapeutics, Inc.	Circular rna compositions and methods
AU2024287308A1 (en)	2023-07-13	2025-12-18	Korro Bio, Inc.	Rna-editing oligonucleotides and uses thereof
WO2025024334A1 (en)	2023-07-21	2025-01-30	Marrow Therapeutics, Inc.	Hematopoietic cell targeting conjugates and related methods
GB202311334D0 (en)	2023-07-24	2023-09-06	Astrazeneca Ab	Multivalent cargo-carrying complexes and uses thereof
GB202311324D0 (en)	2023-07-24	2023-09-06	Astrazeneca Ab	Multivalent cargo-carrying complexes and uses thereof
US20250051771A1 (en)	2023-07-24	2025-02-13	Astrazeneca Ab	Multivalent cargo-carrying complexes and uses thereof
US20250092375A1 (en)	2023-07-25	2025-03-20	Flagship Pioneering Innovations Vii, Llc	Cas endonucleases and related methods
TW202516001A (zh)	2023-07-25	2025-04-16	美商旗艦先鋒創新有限責任（Ｖｉｉ）公司	Ｃａｓ內切酶及相關方法
WO2025034422A1 (en)	2023-08-04	2025-02-13	Alnylam Pharmaceuticals, Inc.	Methods and compositions for treating ctnnb1-associated disorders
TW202521564A (zh)	2023-08-14	2025-06-01	美商英特利亞醫療公司	用於基於細胞之療法的ｃｄ７０ｃａｒ－ｔ組合物及方法
TW202515992A (zh)	2023-08-14	2025-04-16	美商英特利亞醫療公司	用於對轉形生長因子β受體２型（ＴＧＦβＲ２）進行基因修飾之組合物及方法
WO2025038642A1 (en)	2023-08-14	2025-02-20	Intellia Therapeutics, Inc.	Compositions and methods for genetically modifying cd70
WO2025038637A1 (en)	2023-08-14	2025-02-20	Intellia Therapeutics, Inc.	Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2)
WO2025049432A1 (en)	2023-08-28	2025-03-06	Intellia Therapeutics, Inc.	Methods for editing hla-a in cells pre-screened for the absence of one or both alleles of hla-h*01
WO2025049481A1 (en)	2023-08-28	2025-03-06	Intellia Therapeutics, Inc.	Methods of editing an hla-a gene in vitro
WO2025072331A1 (en)	2023-09-26	2025-04-03	Flagship Pioneering Innovations Vii, Llc	Cas nucleases and related methods
WO2025072713A1 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Polymyxins for delivery of agents to the kidney
WO2025072672A2 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Slc6a19-targeting modulatory nucleic acid agents
WO2025072699A1 (en)	2023-09-27	2025-04-03	Judo Bio, Inc.	Aminoglycosides for delivery of agents to the kidney
WO2025076031A2 (en)	2023-10-03	2025-04-10	Alnylam Pharmaceuticals, Inc.	Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
WO2025101501A1 (en)	2023-11-07	2025-05-15	Orna Therapeutics, Inc.	Circular rna compositions
WO2025101994A2 (en)	2023-11-10	2025-05-15	Intellia Therapeutics, Inc.	Compositions, methods, and systems for genomic editing
WO2025117877A2 (en)	2023-12-01	2025-06-05	Flagship Pioneering Innovations Vii, Llc	Cas nucleases and related methods
WO2025128799A1 (en)	2023-12-12	2025-06-19	Korro Bio, Inc.	Double-stranded rna-editing oligonucleotides and uses thereof
WO2025137439A2 (en)	2023-12-20	2025-06-26	Intellia Therapeutics, Inc.	Engineered t cells
WO2025137301A1 (en)	2023-12-20	2025-06-26	Intellia Therapeutics, Inc.	Methods for rapid engineering of cells
WO2025155991A2 (en)	2024-01-19	2025-07-24	Bpgbio, Inc.	Predictive biomarkers for response to coenzyme q10 treatment in pancreatic cancer
WO2025178854A2 (en)	2024-02-19	2025-08-28	Flagship Pioneering Innovations Vii, Llc	Rnai agents targeting cideb and related methods
WO2025177174A1 (en)	2024-02-20	2025-08-28	Diagenode S.A.	Single-cell rna profiling
WO2025184520A1 (en)	2024-02-29	2025-09-04	Intellia Therapeutics, Inc.	Compositions and methods for angiopoietin like 3 (angptl3) editing
US20250313840A1 (en)	2024-03-20	2025-10-09	Vertex Pharmaceuticals Incorporated	Mucin-5b (muc5b) targeted sirna and antisense oligonucleotides and methods of use thereof
WO2025217275A2 (en)	2024-04-10	2025-10-16	Flagship Pioneering Innovations Vii, Llc	Immune cell targeted compositions and related methods
WO2025250751A1 (en)	2024-05-31	2025-12-04	Orna Therapeutics, Inc.	Circular rna compositions and methods
WO2025255308A1 (en)	2024-06-07	2025-12-11	Intellia Therapeutics, Inc.	Cd8 co-receptor chimeric polypeptides in tcr cell therapy
WO2025259743A1 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dual conjugate compounds for extrahepatic delivery
WO2025259747A2 (en)	2024-06-12	2025-12-18	Alnylam Pharmaceuticals, Inc.	Dystrophy myotonic protein kinase (dmpk) irna compositions and methods of use thereof
WO2026006593A1 (en)	2024-06-28	2026-01-02	Orna Therapeutics, Inc.	Synthetic internal ribosome entry sites

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3687808A (en)	1969-08-14	1972-08-29	Univ Leland Stanford Junior	Synthetic polynucleotides
US5034506A (en)	1985-03-15	1991-07-23	Anti-Gene Development Group	Uncharged morpholino-based polymers having achiral intersubunit linkages
JP2528107B2 (ja) *	1985-03-15	1996-08-28	サマ−トン，ジエ−ムス	ポリヌクレオチド測定試薬と方法
EP0260032B1 (en) *	1986-09-08	1994-01-26	Ajinomoto Co., Inc.	Compounds for the cleavage at a specific position of RNA, oligomers employed for the formation of said compounds, and starting materials for the synthesis of said oligomers
US4908307A (en) *	1986-12-19	1990-03-13	Karin D. Rodland	Hybridization method and probe for detecting nucleic acid sequences
EP0348458B1 (en) *	1987-11-30	1997-04-09	University Of Iowa Research Foundation	Dna molecules stabilized by modifications of the 3'-terminal phosphodiester linkage and their use as nucleic acid probes and as therapeutic agents to block the expression of specifically targeted genes
US5403711A (en) *	1987-11-30	1995-04-04	University Of Iowa Research Foundation	Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
US4867187A (en) *	1988-03-22	1989-09-19	Rainsinger Enterprises, Inc.	Umbrella with removable radio handle
AU623642B2 (en) *	1988-03-24	1992-05-21	University Of Iowa Research Foundation, The	Catalytic hybridization systems for the detection of nucleic acid sequences based on their activity as cofactors in catalytic reactions in which a complementary labeled nucleic acid probe is cleaved
DE3814095A1 (de) *	1988-04-26	1989-11-09	Hans F W Spradau	Verfahren zur herstellung von ethylacetat
DE68929361T2 (de) *	1988-04-27	2002-06-20	Isis Pharmaceuticals, Inc.	Oligoribonukleotid-Derivate und Verwendung davon als Antiviral Arzneimittel
DE3915462A1 (de) *	1989-03-03	1990-09-06	Europ Lab Molekularbiolog	Verwendung von 2-tert.-alkylimino-2-di-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)-(pfeil abwaerts)(pfeil abwaerts)4(pfeil abwaerts)-alkylamino- 1,3-di-c(pfeil abwaerts)1(pfeil abwaerts)(pfeil abwaerts)-(pfeil abwaerts)(pfeil abwaerts)3(pfeil abwaerts)-alkyl-perhydro-1,3,2-diazaphosphorin fuer 0-substituierungsreaktionen von ribonukleosiden
DE3916871A1 (de) *	1989-05-24	1990-11-29	Boehringer Mannheim Gmbh	Modifiziertes phosphoramidit-verfahren zur herstellung von modifizierten nukleinsaeuren
US5256775A (en) *	1989-06-05	1993-10-26	Gilead Sciences, Inc.	Exonuclease-resistant oligonucleotides
WO1990015814A1 (en) *	1989-06-20	1990-12-27	Meiogenics, Inc.	Nuclease resistant, single-stranded, non-naturally occurring nucleic acid molecules
US5134066A (en) *	1989-08-29	1992-07-28	Monsanto Company	Improved probes using nucleosides containing 3-dezauracil analogs
US5354656A (en) *	1989-10-02	1994-10-11	Stratagene	Method of DNA sequencing
EP0497875B1 (en) *	1989-10-24	2000-03-22	Isis Pharmaceuticals, Inc.	2' modified oligonucleotides
US5623065A (en) *	1990-08-13	1997-04-22	Isis Pharmaceuticals, Inc.	Gapped 2' modified oligonucleotides
US5459255A (en) *	1990-01-11	1995-10-17	Isis Pharmaceuticals, Inc.	N-2 substituted purines
US5955589A (en) *	1991-12-24	1999-09-21	Isis Pharmaceuticals Inc.	Gapped 2' modified oligonucleotides
US5220007A (en) *	1990-02-15	1993-06-15	The Worcester Foundation For Experimental Biology	Method of site-specific alteration of RNA and production of encoded polypeptides
US5149797A (en) *	1990-02-15	1992-09-22	The Worcester Foundation For Experimental Biology	Method of site-specific alteration of rna and production of encoded polypeptides
JPH03240795A (ja) *	1990-02-15	1991-10-28	Ajinomoto Co Inc	新規オリゴヌクレオチド誘導体及び抗ウイルス剤への使用
US5658731A (en) *	1990-04-09	1997-08-19	Europaisches Laboratorium Fur Molekularbiologie	2'-O-alkylnucleotides as well as polymers which contain such nucleotides
DE4037363A1 (de) *	1990-04-09	1991-10-10	Europ Lab Molekularbiolog	2-0-alkylnukleotide sowie polymere, die solche nukleotide enthalten
ATE147098T1 (de) *	1990-10-12	1997-01-15	Max Planck Gesellschaft	Abgeänderte ribozyme
DE4110085A1 (de) *	1991-03-27	1992-10-01	Boehringer Ingelheim Int	2'-o-alkyl-oligoribonukleotide, verfahren zu deren herstellung und deren verwendung als antisense-oligonukleotide
DK51092D0 (da) *	1991-05-24	1992-04-15	Ole Buchardt	Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf
MX9207334A (es) *	1991-12-18	1993-08-01	Glaxo Inc	Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
CA2126691C (en) *	1991-12-24	2003-05-06	Phillip Dan Cook	Gapped 2' modified oligonucleotides
US5856455A (en) *	1991-12-24	1999-01-05	Isis Pharmaceuticals, Inc.	Gapped 2'-modified oligonucleotides
US5525468A (en) *	1992-05-14	1996-06-11	Ribozyme Pharmaceuticals, Inc.	Assay for Ribozyme target site
US5652355A (en) *	1992-07-23	1997-07-29	Worcester Foundation For Experimental Biology	Hybrid oligonucleotide phosphorothioates
JP5175749B2 (ja)	2009-01-13	2013-04-03	三洋電機株式会社	搬送装置、制御装置及びプログラム
DE102009039097B3 (de)	2009-08-27	2010-11-25	Siemens Aktiengesellschaft	Verfahren zum Übertragen von Daten in einem Sensornetzwerk, Sensorknoten und Zentral-Rechner
JP2013503626A (ja)	2009-09-08	2013-02-04	ネオファームシーオー．，エルティーディー．	グルカゴン受容体に対する抗体と、それらの使用
WO2011065011A1 (ja)	2009-11-26	2011-06-03	旭化成エレクトロニクス株式会社	タッチパネル装置及びタッチパネルのタッチ入力点間距離検出方法
WO2012005769A1 (en)	2010-07-09	2012-01-12	Telecommunication Systems, Inc.	Location privacy selector
US8600545B2 (en)	2010-12-22	2013-12-03	Titanium Metals Corporation	System and method for inspecting and sorting particles and process for qualifying the same with seed particles
CN103186763B (zh)	2011-12-28	2017-07-21	富泰华工业（深圳）有限公司	人脸识别系统及方法
JP5488625B2 (ja)	2012-02-13	2014-05-14	株式会社デンソー	ダブルステータ型同期モータ
US9006110B1 (en)	2013-11-08	2015-04-14	United Microelectronics Corp.	Method for fabricating patterned structure of semiconductor device

1992
- 1992-12-23 CA CA002126691A patent/CA2126691C/en not_active Expired - Lifetime
- 1992-12-23 EP EP00202252A patent/EP1044987B1/en not_active Expired - Lifetime
- 1992-12-23 WO PCT/US1992/011339 patent/WO1993013121A1/en not_active Ceased
- 1992-12-23 EP EP06075176A patent/EP1695979B1/en not_active Revoked
- 1992-12-23 AT AT06075176T patent/ATE515510T1/de not_active IP Right Cessation
- 1992-12-23 DE DE69232032T patent/DE69232032T3/de not_active Expired - Lifetime
- 1992-12-23 DK DK06075176.5T patent/DK1695979T3/da active
- 1992-12-23 EP EP93902851A patent/EP0618925B2/en not_active Expired - Lifetime
- 1992-12-23 KR KR1019940702197A patent/KR940703846A/ko not_active Ceased
- 1992-12-23 JP JP05511953A patent/JP3131222B2/ja not_active Expired - Fee Related
- 1992-12-23 AT AT93902851T patent/ATE204879T1/de not_active IP Right Cessation
- 1992-12-23 AU AU34275/93A patent/AU669353B2/en not_active Expired
- 1992-12-23 DK DK93902851.0T patent/DK0618925T4/da active
- 1992-12-23 AT AT00202252T patent/ATE317848T1/de not_active IP Right Cessation
- 1992-12-23 DE DE69233599T patent/DE69233599T2/de not_active Expired - Lifetime
1998
- 1998-08-31 US US09/144,611 patent/US6146829A/en not_active Expired - Fee Related
1999
- 1999-12-01 US US09/453,514 patent/US6326199B1/en not_active Expired - Fee Related
2000
- 2000-05-16 JP JP2000143468A patent/JP2001002696A/ja active Pending
2001
- 2001-09-12 US US09/951,052 patent/US20050112563A9/en not_active Abandoned
2003
- 2003-06-20 US US10/601,242 patent/US20040038274A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US6146829A (en)	2000-11-14
DE69232032D1 (de)	2001-10-04
EP0618925B1 (en)	2001-08-29
AU669353B2 (en)	1996-06-06
EP1695979A2 (en)	2006-08-30
DK0618925T4 (da)	2012-07-09
US20050112563A9 (en)	2005-05-26
EP1044987A3 (en)	2001-10-04
EP0618925B2 (en)	2012-04-18
JP2001002696A (ja)	2001-01-09
EP1695979A3 (en)	2006-09-06
EP1044987B1 (en)	2006-02-15
AU3427593A (en)	1993-07-28
US20020160379A1 (en)	2002-10-31
EP1695979B1 (en)	2011-07-06
EP1044987A2 (en)	2000-10-18
CA2126691A1 (en)	1993-07-08
ATE515510T1 (de)	2011-07-15
EP0618925A4 (en)	1997-01-02
JPH06511155A (ja)	1994-12-15
DE69233599T2 (de)	2006-12-14
DE69232032T3 (de)	2012-09-13
DE69232032T2 (de)	2002-06-06
KR940703846A (ko)	1994-12-12
WO1993013121A1 (en)	1993-07-08
DK0618925T3 (da)	2001-11-12
JP3131222B2 (ja)	2001-01-31
EP0618925A1 (en)	1994-10-12
US20040038274A1 (en)	2004-02-26
DE69233599D1 (de)	2006-04-20
US6326199B1 (en)	2001-12-04
CA2126691C (en)	2003-05-06
ATE204879T1 (de)	2001-09-15
ATE317848T1 (de)	2006-03-15

Publication	Publication Date	Title
DK1695979T3 (da)	2011-10-10	Gappede modificerede oligonukleotider
DE69729179D1 (de)	2004-06-24	Kohlenhydratmodifizierte luckenhafte oligonukleotide
DE69430818D1 (de)	2002-07-18	Pns-dns-pns-chimäre makromoleküle
ATE419262T1 (de)	2009-01-15	2'-o-acetamido-modifizierte monomere und oligomere
DE69732535D1 (de)	2005-03-24	Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression
WO1995004162A3 (en)	1995-06-01	Dna sequencing enzymes
ATE292141T1 (de)	2005-04-15	Oligoribonukleotide und ribonucleasen zur spaltung von rns
DE69403642D1 (de)	1997-07-10	7-deazapurin modifizierte oligonukleotide
WO1998019167A3 (en)	1998-09-03	Cell stress regulated human mhc class i gene
DE68926455D1 (de)	1996-06-13	Verfahren zur identifizierung von bakterien
EP0870036A4 (en)	2000-01-19	SYNTHETIC MAMMAL ALPHA-N-AECTYL GLUCOSAMINIDASE AND ENCODING GENETIC SEQUENCES THEREFOR
TR199700842T1 (xx)	1998-01-21	�nsan DNase I Varyantlar�.
FR2638090B1 (fr)	1993-10-15	Sequences de nucleotides exprimant l'adenyl cyclase de b. anthracis, proteines ayant l'activite de cette adenyl cyclase et applications biologiques
WO1993013204A3 (de)	1993-08-05	Mittel zur stimulierung der teilungsaktivität tierischer zellen
ATE108834T1 (de)	1994-08-15	Spezifische nukleinsäurefragmente des menschlichen villingens, ihre anwendung für diagnostische zwecke.